What we measure
The 2017 Access to Vaccines Index evaluates how 8 major vaccine companies are improving access to preventive vaccines for 69 priority diseases – including HIV/AIDS, Ebola and Zika – in 107 high-need countries. Find out more about the scope of the Index research.
How we measure
The 2017 Access to Vaccines Index used the first metrics for mapping how vaccine developers and manufacturers are addressing access to vaccines. There are 13 metrics and three Research Areas: Research & Development, Pricing & Registration, and Manufacturing & Supply.
The research process
In 2016, the Foundation’s researchers measured vaccine company behaviour using a rigorous process of data-collection, verification, scoring and analysis in preparation for publishing the 2017 Access to Vaccines Index. Find out more about what this process involves.
How we work with experts
The Access to Vaccines Index methodology was developed in 2015 and reflects what stakeholders expect from vaccine developers and manufacturers when it comes to access to vaccines. Find out more about how the methodology was developed.
The context
The discovery of vaccines has played a central role in some of the most significant achievements in global public health. Vaccination protects children from disease, giving them the opportunity to thrive and realise their full potential. It has had an unparalleled impact on the reduction of childhood mortality.
